Randi Isaacs, M.D.
Executive Director and Clinical Site Head of Translational Clinical Oncology, Novartis Institutes for Biomedical Research
Dr. Randi Isaacs is Executive Director and Clinical Site Head of Translational Clinical Oncology at Novartis Institutes for Biomedical Research where she oversees multiple clinical oncology programs and serves as the clinical liaison for the Novartis CAR-T collaboration with the University of Pennsylvania, and as the clinical liaison for the business development and licensing team, where she is responsible for evaluation and due diligence of potential assets for license or acquisition. She was previously Director of Global Oncology at Schering Plough, Head of Oncology Biologics at Merck, and Associate Director of Clinical Research at Sandoz. Before moving into industry, she held academic positions including Assistant Professor of Medicine, Hematology/Oncology division at the State University of New York Health Sciences Center, and Clinical Assistant Professor in Hematology/Oncology at the University of Medicine and Dentistry of New Jersey. Her major research interests are in the area of novel therapeutic approaches in oncology, including biologic agents, molecularly targeted therapies, immunotherapy and CAR-T cells for the treatment of solid tumors and hematologic malignancies, as well as translational approaches for patient selection strategies and biomarker development.
Dr. Isaacs received her B.A. in chemistry from Wellesley College and her M.D. from Dartmouth Medical School. She spent one year in the MS program in epidemiology at Harvard School of Public Health. She was a resident and postdoctoral fellow at UCSF, and a medical Hematology/Oncology Fellow at Memorial Sloan Kettering.